Publikationen können Sie auch über Pubmed abfragen.

Publikationsliste

1. Grünwald V, Ivanyi P, Zschäbitz S, Wirth M, Staib P, Schostak M, Dargatz P, Müller L, Metz M, Bergmann L, Steiner T, Welslau M, Lorch A, Rafiyan R, Hellmis E, Darr C, Schütt P, Meiler J, Kretz T, Loidl W, Flörcken A, Mänz M, Hinke A, Hartmann A, Grüllich C. Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass). Eur Urol. 2023 Dec;84(6):571-57.
2. Bergmann L, Weber S, Hartmann A, Ahrens M. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther. 2021 Nov;21(11):1273-1286.
3. Grünwald V, Hilser T, Meiler J, Goebell PJ, Ivanyi P, Strauss A, Hartmann A, Bedke J, Bergmann L. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study). Oncol Res Treat. 2022;45(5):272-280.Osinga TE, Oosting SF, van der Meer P, de Boer RA, Kuenen BC, Rutgers A, Bergmann L, Oude Munnink TH, Jalving M, van Kruchten M. Immune checkpoint inhibitor-associated myocarditis : Case reports and a review of the literature. Neth Heart J. 2022 Jun;30(6):295-301.
4. Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Kuczyk MA. Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms [Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]. Aktuelle Urol. 2022 Sep;53(5):403-415.Bergmann L, Weber S, Hartmann A, Ahrens M. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview. Expert Rev Anticancer Ther. 2021 Nov;21(11):1273-1286.
5. Strauss A, Schmid M, Rink M, Moran M, Bernhardt S, Hubbe M, Bergmann L, Schlack K, Boegemann M. Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. Future Oncol. 2021 Jun;17(18):2325-2338.
6. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021 Apr 8;384(14):1289-1300.(Investigator)
7. Araujo-Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. ESMO Open. 2020 Dec 16;6(1):100008. doi: 10.1016/j.esmoop.2020.100008.
8. Bergmann L, Grünwald V, Maute L, Grimm MO, Weikert S, Schleicher J, Klotz T, Greiner J, Flörcken A, Hartmann A, Gauler T. A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society. Oncol Res Treat. 2020;43(7-8):333-339.
9. Boegemann M, Schlack K, Rink M, Bernhardt S, Moran M, Hubbe M, Bergmann L, Schmid M, Strauss A. Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. Future Oncol. 2020 Oct 6. doi: 10.2217/fon-2020-0548. Epub ahead of print. PMID: 33021843.
10. Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Keilholz U, Kuczyk MA. Interdisziplinäre Empfehlungen zur Behandlung des fortgeschrittenen Nierenzellkarzinoms [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]. Aktuelle Urol. 2020 Oct 7. German. doi: 10.1055/a-1252-1780.
11. Goebell PJ, Ivanyi P, Bedke J, Bergmann L, Berthold D, Boegemann M, Busch J, Doehn C, Krege S, Retz M, Amsberg GV, Grimm MO, Gruenwald V. Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncol. 2020 Sep 23. doi: 10.2217/fon-2020-0403. Online ahead of print.
12. Ahrens M, Hartmann A, Bergmann L.  What is new in the diagnosis and therapy of renal cell carcinoma?  Dtsch Med Wochenschr. 2020 Jun;145(11):734-739.
13. Rexer H, Bergmann L, Steiner T. A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO. Aktuelle Urol. 2020 Jun;51(3):236-238.
14. Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2020 Feb;126:1-10.
15. Ahrens M, Scheich S, Hartmann A, Bergmann L. IAG-N Interdisciplinary Working Group Kidney Cancer of the German Cancer Society.Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options. Oncol Res Treat. 2019;42(3):128-135.
16. Miller K, Bergmann L, Doehn C, Gschwend JE, Kuczyk MA. Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma.  Aktuelle Urol. 2019 Sep 4. doi: 10.1055/a-0972-0914. [Epub ahead of print] German
17. Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Eur J Cancer. 2019 Jun;114:128-136.
18. Goebell PJ, Hermann E, Kube U, Doehn C, Marschner N, Dietel A, Blumenstengel K, Grimm MO, Scheffler M, Rogler A, Bergmann L. Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma with Everolimus: The EVERPRO Study.Oncol Res Treat. 2019;42(1-2):57-66.
19. *Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators (Bergmann, investigator). Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med. 2018 Apr 5;378(14):1277-1290
20. *Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study (Bergmann, investigator) .Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1530-1542
21. Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients with Sunitinib-Treated Cancer. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613.
22. Rexer H, Steiner T, Bergmann L. Nivolumab combined with ipilimumab versus sunitinib monotherapy - SUNNIFORECAST AN 41/16 of the AUO: A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma. Urologe A. 2017 Jun;56(6):802-803.
23. Miller K, Bergmann L, Doehn C, Gschwend J, Keilholz U. Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma. Aktuelle Urol. 2017 Feb;48(1):72-78.
24. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016 Dec 8;375(23):2246-2254. *
25. Maute L, Bergmann L. Systemic therapy of metastatic renal cell carcinoma. Dtsch Med Wochenschr. 2016 Apr;141(7):466-9.
26. Rummel M, Kaiser U, Balser C, Stauch M, Brugger W, Welslau M, Niederle N, Losem C, Boeck HP, Weidmann E, von Gruenhagen U, Mueller L, Sandherr M, Hahn L, Vereshchagina J, Kauff F, Blau W, Hinke A, Barth J; Study Group Indolent Lymphomas.Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7.*
27. Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist. 2016 Jan;21(1):102-9.
28. Bergmann L, Enzmann H, Thirstrup S, Schweim JK, Widera I, Zwierzina H. Access to innovative oncology medicines in Europe. Ann Oncol. 2016 Feb;27(2):353-6.
29. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23.
30. Albiges L, Kube U, Eymard JC, Schmidinger M, Bamias A, Kelkouli N, Mraz B, Florini S, Guderian G, Cattaneo A, Bergmann L. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies. Eur J Cancer. 2015 Nov;51(16):2368-74.
31. Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. Leukemia. 2016 Apr;30(4):984-7.
32. Bergmann L, Brugger W, Herr W, Mackensen A, Multhoff G. What opportunities does Immuno-oncology indicate for overarching long-term survival?. Oncol Res Treat. 2015;38 Suppl 3:6-11.
33. Bergmann L, Kube U, Doehn C, Steiner T, Goebell PJ, Kindler M, Herrmann E, Janssen J, Weikert S, Scheffler MT, Schmitz J, Albrecht M, Staehler M. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer. 2015 Apr 18;15:303.
34.  Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend J, Kuczyk M. Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma. Aktuelle Urol. 2015 Mar;46(2):151-7.
35. Bergmann L, Maute L, Heil G, Rüssel J, Weidmann E, Köberle D, Fuxius S, Weigang-Köhler K, Aulitzky WE, Wörmann B, Hartung G, Moritz B, Edler L, Burkholder I, Scheulen ME, Richly H. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur J Cancer. 2015 Jan;51(1):27-36.
36. Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014 Nov;167(4):466-77.*
37. Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE. Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice. Oncol Res Treat. 2014;37(3):136-41.
38. Maute L, Grünwald V, Weikert S, Kube U, Gauler T, Kahl C, Burkholder I, Bergmann L. Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis. J Cancer Res Clin Oncol. 2014 May;140(5):823-7. doi: 10.1007/s00432-014-1610-x. Epub 2014 Feb 21.
39.  Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M. Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol. 2014 Jan;45(1):39-44. doi: 10.1055/s-0033-1363228.
40. Bergmann L, Enzmann H, Broich K, Hebborn A, Marsoni S, Goh L, Smyth JF, Zwierzina H. Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe? Ann Oncol. 2014 Feb;25(2):303-6.
41. Bergmann L, Maute L, Guschmann M. Temsirolimus for advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2014 Jan;14(1):9-21.
42. Schrader AJ, Seseke S, Keil C, Herrmann E, Goebell PJ, Weikert S, Steffens S, Bergmann L, Roigas J, Steiner T. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer. Eur Urol. 2014 Aug;66(2):275-81.
43. Bergmann L, Goebell PJ, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Steiner G, Jakob A, Staehler MD, Steiner T, Overkamp F, Albrecht M, Guderian G, Doehn C. Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. Onkologie. 2013;36(3):95-100.
44. Hartmann S, Agostinelli C, Diener J, Döring C, Fanti S, Zinzani PL, Gallamini A, Bergmann L, Pileri S, Hansmann ML. GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. BMC Cancer. 2012 Dec 10;12:586. doi: 10.1186/1471-2407-12-586.
45. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group.Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol. 2013 Dec;64(6):994-1002.
46. Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M, Wirth M. Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma. Aktuelle Urol. 2013 Jan;44(1):45-9.
47. Glienke W, Maute L, Wicht J, Bergmann L. The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines. Tumour Biol. 2012 Jun;33(3):757-65.
48. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.
49. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.
50. Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol. 2011 Nov;87(5):426-33.
51.  Miller K, Bergmann L, Gschwend J, Keilholz U. Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma. Aktuelle Urol. 2011 Jul;42(4):242-6.
52. Schultheis B, Strumberg D, Bergmann L, Graeven U, Hanauske AR, Lipp R, Schuette J, Saito K, Scigalla P, Scheulen ME. Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Invest New Drugs. 2012 Jun;30(3):1184-92.
53. Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schöffski P, Witthohn K, Lentzen H. The preclinical and clinical activity of aviscumine: a potential anticancer drug. Eur J Cancer. 2011 Jul;47(10):1450-7.
54. Glienke W, Hausmann E, Bergmann L. Targeting STAT3 signaling in pancreatic cancer promotes antiapoptotic gene expression. Pancreas. 2011 Mar;40(2):323-4.
55. Glienke W, Hausmann E, Bergmann L. Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines. Tumour Biol. 2011 Jun;32(3):493-500.
56. Strumberg D, Bergmann L, Graeven U, Hanauske A, Lipp R, Schuette J, Schultheis B, Scigalla P, Urrea P, Scheulen ME. First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group). Int J Clin Pharmacol Ther. 2010 Jul;48(7):470-2. No abstract available.
57. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15;116(18):4256-65.
58. Miller K, Bergmann L, Albers P, Gschwend J, Jäger E, Keilholz U. Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma. Aktuelle Urol. 2010 May;41(3):193-6.
59. Bergmann L, Miller K. Outlook: Future therapy of renal cell carcinoma. Onkologie. 2010;33 Suppl 1:18-20.
60. Bergmann L. Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma. Onkologie. 2010;33 Suppl 1:2-4.
61. Bergmann L, Miller K. The introduction of targeted drugs. Onkologie. 2010;33 Suppl 1:1.
62. Bergmann L, Berns B, Dalgleish AG, von Euler M, Hecht TT, Lappin GL, Reed N, Palmeri S, Smyth J, Embacher-Aichorn S, Zwierzina H; Biotherapy Development Association. Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Ann Oncol. 2010 Aug;21(8):1573-8. Review.
63. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. Cancer Invest. 2010 Feb;28(2):166-71.
64. McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, Jönsson B, Kallen KJ, Newling D, Nüssler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H; Biotherapy Development Association. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol. 2009 Mar;20(3):403-12.
65. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol. 2009 May;63(6):1097-102.
66. Glienke W, Maute L, Wicht J, Bergmann L. Wilms’ Tumor Gene 1 (WT1) as a Target in Curcumin Treatment of Pancreatic Cancer Cells. Eur J Cancer, 2009, 2009 Mar;45(5):874-80. Epub 2009 Feb 3
67. McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, Jönsson B, Kallen KJ, Newling D, Nüssler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H; Biotherapy Development Association.Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.Ann Oncol. 2008 Oct 14.
68. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T.Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.Cancer Chemother Pharmacol. 2008 Sep 26. [Epub ahead of print]
69. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 9;372(9637):449-56. Epub 2008 Jul 22. *
70. Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2008 Aug;44(12):1657-62.
71. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 1;358(18):1909-18. *
72. Glienke W, Maute L, Koehl U, Esser R, Milz E, Bergmann L..Effective treatment of leukemic cell lines with wt1 siRNA. Leukemia. 2007 Oct;21(10):2164-70. Epub 2007 Aug 9.
73. Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma] Aktuelle Urol. 2007 Jul;38(4):328-30. German.
74. Chow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D, Mitrou PS, Bergmann L, Ottmann OG, Boehrer S. The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines. Leuk Lymphoma. 2007 Jul;48(7):1379-1388
75. Bergmann L, Hirschfeld S, Morris C, Palmeri S,  Stone A and Biotherapy Development Association (BDA). Progression-free survival as an end-point in clinical trials of biotherapeutic agents. Eur J Cancer, 2007, suppl.5:23-28
76. Bergmann L.. Erlotinib in pancreatic cancer. Eu J Cancer 2007, suppl.5: 7-8
77. Glienke W, Chow KU, Bauer N, Bergmann L..Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma. 2006 Aug;47(8):1629-38.
78. Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S, Mousset S, Hoelzer D, Martin H.High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol. 2005 Oct;84(11):748-54. Epub 2005 Jul 7.
79. Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM.Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2004 Jun;45(6):1181-4.
80. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol. 2004 Aug;83(8):498-503. Epub 2004 May 20.
81. Hübinger G, Schneider C, Stöhr D, Ruff H, Kirchner D, Schwänen C, Schmid M, Bergmann L, Müller E.CD30-induced up-regulation of the inhibitor of apoptosis genes cIAP1 and cIAP2 in anaplastic large cell lymphoma cells.Exp Hematol. 2004 Apr;32(4):382-9.
82. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W, Lübbert M, Noens L, Schlimok G, Arnold R, Kirchner H, Ganser A.Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial. Ann Hematol. 2004 Jun;83(6):336-44. Epub 2004 Mar 18.
83. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).J Clin Oncol. 2004 Apr 1;22(7):1188-94. Epub 2004 Feb 23.
84. Schirrmeister H, Buck AK, Bergmann L, Reske SN, Bommer M.Positron emission tomography (PET) for staging of solitary plasmacytoma.Cancer Biother Radiopharm. 2003 Oct;18(5):841-5.
85. Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G.Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol. 2003 Jun;31(6):504-11.
86. Hofmann WK, Seipelt G, Langenhan S, Reutzel R, Schott D, Schoeffski O, Illiger HJ, Hartmann F, Balleisen L, Franke A, Fiedler F, Huber C, Rasche H, Bergmann L, Ganser A, Pott C, Pasold R, Rudolph C, Ottmann OG, Gökbuget N, Hoelzer D.Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.Ann Hematol. 2002 Oct;81(10):570-4. Epub 2002 Oct 17.
87. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Döhner H, Heimpel H.Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood. 2002 Nov 15;100(10):3749-56.
88. Schwänen C, Hecker T, Hübinger G, Wölfle M, Rittgen W, Bergmann L, Karakas T.In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.Leukemia. 2002 Oct;16(10):2096-105.
89. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, Schmitt M.Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia- associated antigen in acute and chronic myeloid leukemia.Exp Hematol. 2002 Sep;30(9):1029-35.
90. Rummel MJ, Chow KU, Karakas T, Jäger E, Mezger J, von Grünhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.Eur J Cancer. 2002 Sep;38(13):1739-46.
91. Schirrmeister H, Bommer M, Buck AK, Müller S, Messer P, Bunjes D, Döhner H, Bergmann L, Reske SN.Initial results in the assessment of multiple myeloma using 18F-FDG PET.Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):361-6.
92. Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L..The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia.Leukemia. 2002 May;16(5):846-54.
93. Hübinger G, Schmid M, Linortner S, Manegold A, Bergmann L, Maurer U.Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol. 2001 Oct;29(10):1226-35.
94. Reske SN, Bunjes D, Buchmann I, Seitz U, Glatting G, Neumaier B, Kotzerke J, Buck A, Martin H, Döhner H, Bergmann L..Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation.Eur J
95. Bergmann L..Significance of chromosomal aberrations in CLL. Onkologie. 2001 Apr;24(2):176. No abstract available.
96. Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN.Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.Blood. 2001 Aug 1;98(3):565-72.
97. Bergmann L..[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer] Strahlenther Onkol. 2001 May;177(5):273-4. German. No abstract available.
98. Graf J, Merk B, Maurer U, Müller E, Bergmann L..Identification of novel polymorphisms in intron 7 of the human p53 gene in acute myeloid leukemia and healthy donors.  Leuk Lymphoma. 2001 May;41(5-6):655-8.
99. Hübinger G, Müller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, Sigg I, Graf J, Bergmann L..CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.Oncogene. 2001 Feb 1;20(5):590-8.
100. Lundin J, Kimby E, Bergmann L, Karakas T, Mellstedt H, Osterborg A.Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. Br J Haematol. 2001 Jan;112(1):155-60.
101. Ringdén O, Labopin M, Gorin NC, Schmitz N, Schaefer UW, Prentice HG, Bergmann L, Jouet JP, Mandelli F, Blaise D, Fouillard L, Frassoni F; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol. 2000 Dec;111(4):1130-7.
102. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Huebsch S, Maurer U, Bergmann L, Schmitt M.Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol. 2000 Dec;28(12):1413-22.
103. Maurer U, Jehan F, Englert C, Hubinger G, Weidmann E, DeLuca HF, Bergmann L..The Wilms' tumor gene product (WT1) modulates the response to 1,25-dihydroxyvitamin D3 by induction of the vitamin D receptor. J Biol Chem. 2001 Feb 9;276(6):3727-32. Epub 2000 Oct 24.
104. Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A, Bergmann L, Visani G, Cornelissen J, De Witte T, Bosi A, Frassoni F, Gorin NC.No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000 Aug;110(2):308-14.
105. Reuter CW, Morgan MA, Bergmann L..Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?Blood. 2000 Sep 1;96(5):1655-69. Review.
106. Bunjes D, Duncker C, Wiesneth M, Stefanic M, Dohr D, Harsdorf S, Karakas T, Reske SN, Bergmann L..CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation.Bone Marrow Transplant. 2000 May;25 Suppl 2:S9-11.
107. Duncker C, Dohr D, Harsdorf S, Duyster J, Stefanic M, Martini C, Treiber M, Hertenstein B, Novotny J, Arnold R, Heimpel H, Bergmann L, Bunjes D.Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome. Bone Marrow Transplant. 2000 Jun;25(12):1263-8.
108. Munzert G, Kreitmeier S, Bergmann L..Normal structure of NFKB2, C-REL and BCL-3 gene loci in lymphoproliferative and myeloproliferative disorders. Leuk Lymphoma. 2000 Jul;38(3-4):395-400.
109. Griesshammer M, Kubanek B, Beneke H, Heimpel H, Bangerter M, Bergmann L, Schrezenmeier H.Serum erythropoietin and thrombopoietin levels in patients with essential thrombocythaemia. Leuk Lymphoma. 2000 Feb;36(5-6):533-8.
110. Kotzerke J, Glatting G, Seitz U, Rentschler M, Neumaier B, Bunjes D, Duncker C, Dohr D, Bergmann L, Reske SN.Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med. 2000 Mar;41(3):531-7.
111. Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).Ann Hematol. 2000 Jan;79(1):30-5.
112. Hübinger G, Scheffrahn I, Müller E, Bai R, Duyster J, Morris SW, Schrezenmeier H, Bergmann L..The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.Exp Hematol. 1999 Dec;27(12):1796-805.
113. Griesshammer M, Bergmann L, Pearson T.Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin Haematol. 1998 Dec;11(4):859-74. Review.
114. Griesshammer M, Beneke H, Nussbaumer B, Grünewald M, Bangerter M, Bergmann L.. Increased platelet surface expression of P-selectin and thrombospondin as markers of platelet activation in essential thrombocythaemia. Thromb Res. 1999 Nov 1;96(3):191-6.
115. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L.. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999;38(6):799-804.
116. Krauter J, Wattjes MP, Nagel S, Heidenreich O, Krug U, Kafert S, Bunjes D, Bergmann L, Ganser A, Heil G. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol. 1999 Oct;107(1):80-5.
117. Rummel MJ, Chow KU, Jäger E, Leimer L, Hossfeld DK, Bergmann L, Peters HD, Hansmann ML, Meyer A, Hoelzer D, Mitrou PS.Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma. 1999 Sep;35(1-2):129-38.
118. Bangerter M, Griesshammer M, Bergmann L..Progress in medical imaging of lymphoma and Hodgkin's disease. Curr Opin Oncol. 1999 Sep;11(5):339-42. Review.
119. Krauter J, Ganser A, Bergmann L, Raghavachar A, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Heil G.Association between structural and numerical chromosomal aberrations in acute myeloblastic leukemia: a study by RT-PCR and FISH in 447 patients with de-novo AML. Ann Hematol. 1999 Jun;78(6):265-9.
120. Kröger MJ, Menzel T, Gschwend JE, Bergmann L..Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy--a pilot study. Anticancer Res. 1999 Mar-Apr;19(2C):1553-5.
121. Raab C, Weidmann E, Schmidt A, Bergmann L, Badenhoop K, Usadel KH, Haak T.The effects of interleukin-2 treatment on endothelin and the activation of the hypothalamic-pituitary-adrenal axis.Clin Endocrinol (Oxf). 1999 Jan;50(1):37-44.
122. Möbus V, von Schilling C, Kreienberg R, Wiesneth M, Bergmann L, Frickhofen N.[Stem cell supported high dose chemotherapy (HDCT) in primary treatment of advanced ovarian carcinoma] Praxis (Bern 1994). 1999 Mar 18;88(12):507-12. Review. German.
123. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H.Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count.  J Intern Med. 1999 Mar;245(3):295-300.
124. Rummel MJ, Käfer G, Pfreundschuh M, Jäger E, Reinhardt U, Mitrou PS, Hoelzer D, Bergmann L..  Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.Ann Oncol. 1999 Feb;10(2):183-8.
125. Rummel MJ, Chow KU, Jäger E, Hossfeld DK, Bergmann L, Peters HD, Hansmann ML, Meyer A, Hoelzer D, Mitrou PS.Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.Ann Oncol. 1999 Jan;10(1):115-7.
126. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, Elsner K, Frickhofen N, Reske SN, Bergmann L..Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.Ann Oncol. 1998 Oct;9(10):1117-22.
127. Krauter J, Peter W, Pascheberg U, Heinze B, Bergmann L, Hoelzer D, Lübbert M, Schlimok G, Arnold R, Kirchner H, Port M, Ganser A, Heil G.Detection of karyotypic aberrations in acute myeloblastic leukaemia: a prospective comparison between PCR/FISH and standard cytogenetics in 140 patients with de novo AML.Br J Haematol. 1998 Oct;103(1):72-8.
128. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L..High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia.Ann Oncol. 1998 Feb;9(2):159-65.
129. Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L..Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood. 1997 Nov 15;90(10):4230-2. No abstract available.
130. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L..The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro.Exp Hematol. 1997 Aug;25(9):945-50.
131. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D.High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997 Aug 1;90(3):1217-25.
132. Bergmann L, Maurer U, Weidmann E.Wilms tumor gene expression in acute myeloid leukemias. Leuk Lymphoma. 1997 May;25(5-6):435-43. Review.
133. Weidmann E, Brieger J, Karakas T, Maurer U, Pascheberg U, Hoelzer D, Mitrou PS, Bergmann L..Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501.Leukemia. 1997 May;11(5):709-13.
134. Geissler RG, Bergmann L, Hacker H, Knupp B, Walker B, Hoelzer D.Severe central nervous adverse effect of intrathecal chemotherapy in a 16-yr-old patient with Burkitt's type lymphoma.Eur J Haematol. 1997 Apr;58(4):286-8. No abstract available.
135. Bergmann L..Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia. 1997 Apr;11 Suppl 2:S29-34. Review.
136. Karakas T, Bergmann L, Stutte HJ, Jäger E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D.Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma. 1996 Dec;24(1-2):121-9.
137. Böhme A, Just-Nübling G, Bergmann L, Shah PM, Stille W, Hoelzer D.Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies.J Antimicrob Chemother. 1996 Dec;38(6):953-61.
138. Hartmann C, Bergmann L..Specular microscopy: from speculative to spectacular microscopy.Ger J Ophthalmol. 1996 Nov;5(6):496-503. Review.
139. Bakos L, Correa CC, Bergmann L, Bonamigo RR, Muller LF.Antiphospholipid antibodies thrombotic syndrome misdiagnosed as Lucio's phenomenon. Int J Lepr Other Mycobact Dis. 1996 Sep;64(3):320-3. No abstract available.
140. Pleyer U, Bergmann L, Krause A, Hartmann C.[Autoimmune diseases of the peripheral cornea. Immunopathology, clinical aspects and therapy] Klin Monatsbl Augenheilkd. 1996 Feb;208(2):73-81. Review. German.
141. Bergmann L, Karakas T, Lautenschlager G, Jager E, Knuth A, Mitrou PS, Hoelzer D. Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma--a multicenter phase II study. Ann Oncol. 1995 Dec;6(10):1019-24.
142. Bergmann L, Karakas T, Knuth A, Lautenschläger G, Mitrou PS, Hoelzer D.Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study. Eur J Cancer. 1995 Dec;31A(13-14):2164-8.
143. Bergmann L, Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. Exp Hematol. 1995 Dec;23(14):1574-80.
144. Böhme A, Just-Nübling G, Bergmann L, Shah PM, Stille W, Hoelzer D.A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients. Infection. 1995 Nov-Dec;23(6):349-55.
145. Brieger J, Weidmann E, Maurer U, Hoelzer D, Mitrou PS, Bergmann L..The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR. Ann Oncol. 1995 Oct;6(8):811-6.
146. Fenchel K, Bergmann L, Wijermans P, Engert A, Pralle H, Mitrou PS, Diehl V, Hoelzer D. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma. 1995 Aug;18(5-6):485-92.
147. Weidmann E, Brieger J, Bergmann L, Hoelzer D, Mitrou PS.AML blasts variably express interleukin 2 receptor alpha, beta or gamma chains without measurable effects on proliferation, cytokine message expression or surface expression of adhesion molecules upon stimulation with interleukin 2.Leuk Res. 1995 Jul;19(7):469-76.
148. Weidmann E, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS.Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol. 1995 Mar;70(3):153-8.
149. Jahn B, Bergmann L, Weidmann E, Brieger J, Fenchel K, Schwulera U, Hoelzer D, Mitrou PS. Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. Leuk Res. 1995 Feb;19(2):73-82.
150. Bergmann L, Heil G, Kolbe K, Lengfelder E, Puzicha E, Martin H, Lohmeyer J, Mitrou PS, Hoelzer D.Interleukin -2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia.Leuk Lymphoma. 1995 Jan;16(3-4):271-9.
151. Radounikli A, Stahl RA, Bergmann L, Schoeppe W, Thaiss F.Characterization of the mononuclear cell infiltrate in the glomerulus of rats with glomerulonephritis. Nephrol Dial Transplant. 1995;10(2):185-90.
152. Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L..The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells.Leukemia. 1994 Dec;8(12):2138-43.
153. Nockher WA, Bergmann L, Scherberich JE.Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients.Clin Exp Immunol. 1994 Dec;98(3):369-74.
154. Jahn B, Brieger J, Fenchel K, Mitrou PS, Bergmann L..In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.Cancer Immunol Immunother. 1994 May;38(5):304-10.
155. Kamps BS, Brodt HR, Staszewski S, Bergmann L, Helm EB.AIDS-free survival and overall survival in HIV infection: the new CDC classification system (1993) for HIV disease and AIDS.Clin Investig. 1994 Mar;72(4):283-7.
156. Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.Cancer. 1993 Sep 1;72(5):1733-42.
157. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W.Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials.Cancer. 1993 Jul 15;72(2):607-14.
158. Lob S, Bergmann L, Müller H, Jacobi V, Hoelzer D.[Pleomorphic T-cell lymphoma. The diagnostic problems, therapeutic possibilities and infection-induced complications] Dtsch Med Wochenschr. 1993 May 28;118(21):780-4. German.
159. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D.Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia.Ann Oncol. 1993 May;4(5):371-5.
160. Ganser A, Heil G, Kolbe K, Maschmeyer G, Fischer JT, Bergmann L, Mitrou PS, Heit W, Heimpel H, Huber C, et al.Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia--initial results.Ann Hematol. 1993 Mar;66(3):123-5.
161. Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS.Rapid cytokine release in cancer patients treated with interleukin-2.J Immunother (1991). 1992 Aug;12(2):123-31.
162. Lob S, Bergmann L, Müller H, Hoelzer D.[Pleomorphic T-cell lymphoma. Its diagnosis and the therapeutic possibilities] Dtsch Med Wochenschr. 1991 Jun 21;116(25):986-91. Review. German. No abstract available.
163. Bergmann L, Weidmann E, Mitrou PS.[The immunotherapy of advanced renal cell carcinoma]Dtsch Med Wochenschr. 1991 Mar 8;116(10):384-90. Review. German. No abstract available.
164. Harstrick A, Schmoll HJ, Köhne-Wömpner CH, Bergmann L, Lammers U, Hohnloser J, Dölken G, Reichhardt P, Siegert W, Natt F, et al.Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol. 1991 Mar;2(3):197-202.
165. Koberda J, Bergmann L, Mitrou PS, Hoelzer D.High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells. J Cancer Res Clin Oncol. 1991;117(5):425-30.
166. Weidmann E, Bergmann L, Hechler P, Mitrou PS. Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2. Cancer Immunol Immunother. 1991;33(6):398-402.
167. Bergmann L..The clinical significance of interleukin-2. Onkologie. 1990 Dec;13(6):416-22. Review.
168. Bergmann L, Weidmann E, Mitrou PS, Runne U, Keilholz U, Bartsch HH, Franks CR. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Onkologie. 1990 Apr;13(2):137-40.
169. Bergmann L, Böttcher W, Seufert RM, Mitrou PS. Quantitative and functional restorations and alterations of peripheral lymphocytes in patients with autologous spleen implantation. Arch Orthop Trauma Surg. 1990;109(2):102-5.
170. Griesinger F, Bergmann L, Barot-Ciorbaru R, Mitrou PS.Intrinsic B lymphocyte defect in untreated patients with Hodgkin's disease. Cancer Immunol Immunother. 1990;32(4):256-60.
171. Bergmann L, Weidmann E, Bungert B, Hechler P, Mitrou PS.Influence of various cytokines on the induction of lymphokine-activated killer cells.Nat Immun Cell Growth Regul. 1990;9(4):265-73.
172. Schmidt A, Kirsten O, Bergmann L, Liebetrau G.[Tumor-like courses in lung sarcoidosis (4 observations)] Pneumologie. 1989 Jun;43(6):290-4. German.
173. Bergmann L.Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers. Eur J Cancer Clin Oncol. 1989;25 Suppl 3:S31-6. Review.
174. Ganser A, Völkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D.Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial. Blood. 1989 Jan;73(1):31-7.
175. Klima A, Klippstein T, Bergmann L, Szepesi S, Ilberg CV.Adjuvant chemotherapy in stage III and IV squamous cell carcinoma of the head and neck. J Laryngol Otol. 1988 Apr;102(4):337-40.
176. Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L., Kolb HJ, Meyer P, Essers U, Queisser U, Vaupel H, et al.[Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897] Onkologie. 1988 Feb;11(1):25-9.
177. Hehlmann R, Anger B, Messerer D, Zankovich R, Bergmann L., Kolb HJ, Meyer P, Essers U, Queisser U, Vaupel H, et al. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut. 1988 Feb;56(2):87-91.
178. Mitrou PS, Fischer C, Huhn D, Rasokat H, Ring J, Bergmann L..Treatment of advanced, progressive epidemic Kaposi's sarcoma (EKS): a phase-II study. Onkologie. 1988 Feb;11(1):61-2.
179. Klima A, von Ilberg C, Bergmann L., Klippstein T, Zoubek A, Mitrou PS, Szepisi S, Jakobi A. [The effect of radio- and chemotherapy on survival in advanced head and neck tumors] Strahlenther Onkol. 1987 May;163(5):297-300. German.
180. Hehlmann R, Heimpel H, Hossfeld DK, Köpcke W, Kolb HJ, Löffler H, Pralle H, Queisser W, Anger B, Bergmann L., et al. [Prospective controlled study of therapy of chronic myeloid leukemia (CML)] Onkologie. 1987 Feb;10(1):28-33. German.
181. Schmoll HJ, Schubert I, Arnold H, Dölken G, Hecht T, Bergmann L, Illiger J, Fink U, Preiss J, Pfreundschuh M, et al. Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin. Int J Androl. 1987 Feb;10(1):311-7.
182. Klima A, von Ilberg C, Bergmann L., Zoubek A, Klippstein T, Mitrou PS, Szepesi S. [Chemotherapy or chemotherapy and radiotherapy in advanced head and neck tumors. A prospective, randomized study comparing the 2 therapeutic modalities] HNO. 1987 Feb;35(2):78-83. German.
183. Bergmann L., Mitrou PS, Demmer-Dieckmann M, Ruhmann FT, Weidmann E.Impaired T- and B-cell functions in patients with Hodgkin's disease. Reduced mitogenic responsibility and Il-2 production is not caused by defective CD4+-cells. Cancer Immunol Immunother. 1987;25(1):59-64.
184. Brodt HR, Helm EB, Werner A, Joetten A, Bergmann L., Klüver A, Stille W. Spontaneous course of LAV/HTLV-III infection. Follow-up of persons from AIDS-risk groups. Dtsch Med Wochenschr. 1986 Aug 1;111(31-32):1175-80. German.
185. Schöfer H, Runne U, Bergmann L., Saller R, Helm EB.[Acute exanthematous eruption of multiple Kaposi sarcomas of the AIDS type in a female drug-addict. Successful chemotherapy with vincristine, bleomycin and dactinomycin] Hautarzt. 1986 Mar;37(3):159-62. German.
186. Bargon J, Kronenberger H, Bergmann L., Buhl R, Meier-Sydow J, Mitrou P.Lymphocyte transformation test in a group of foundry workers exposed to beryllium and non-exposed controls. Eur J Respir Dis Suppl. 1986;146:211-5. No abstract available.
187. Hach V, Bergmann L., Scharrer I, Mitrou P, Mueller-Eckhardt C.Chronic thrombocytopenia in an immunodeficient patient with hemophilia A. Blut. 1985 May;50(5):293-8.
188. Hunsmann G, Schneider J, Bayer H, Kurth R, Werner A, Brede HD, Erfle V, Mellert W, Brodt HR, Bergmann L., et al. Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany. Klin Wochenschr. 1985 Mar 1;63(5):233-5.
189. Bergmann L., Mitrou PS, Kelker W, Weber KC. T-cell subsets in malignant lymphomas and monoclonal gammopathies. Scand J Haematol. 1985 Feb;34(2):170-6.
190. Rust M, Bergmann L., Kühn T, Tuengerthal S, Bartmann K, Mitrou PS, Meier-Sydow J.Prognostic value of chest radiograph, serum-angiotensin-converting enzyme and T helper cell count in blood and in bronchoalveolar lavage of patients with pulmonary sarcoidosis. Respiration. 1985;48(3):231-6.
191. Helm EB, Bergmann L., Elbert M, Mitrou P, Stille W. [Clinical aspects and observations on patients with lymphadenopathy syndrome] Dtsch Med Wochenschr. 1984 Dec 21;109(51-52):1955-62. German.
192. Klippstein TH, Mitrou PS, Kochendörfer KJ, Bergmann L..High-dose adriamycin (ADM) and cis-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study. Cancer Chemother Pharmacol. 1984;13(2):78-81.
193. Bergmann L., Mitrou PS, Weber KC, Kelker W. Imbalances of T-cell subsets in monoclonal gammopathies. Cancer Immunol Immunother. 1984;17(2):112-6.
194. Mitrou PS, Bergmann L..Subpopulations of thymus-dependent blood lymphocytes. Importance for clinical medicine and research. Dtsch Med Wochenschr. 1983 Dec 9;108(49):1888-93. German. No abstract available.
195. Helm EB, Bergmann L., Elbert M, Kurth R, Mitrou PS, Shah PM, Stille W. [Acquired immunodeficiency syndrome (AIDS) in male homosexuals in Frankfurt am Main] MMW Munch Med Wochenschr. 1983 Dec 2;125(48):1129-34. German. No abstract available.
196. Kurth R, Brede HD, Bergmann L., Mitrou PS, Helm EB, Stille W.[Antibodies against human T-cell leukemia virus (HTLV) in male homosexuals with acquired immunodeficiency syndrome]MMW Munch Med Wochenschr. 1983 Dec 2;125(48):1119-23. German. No abstract available.
197. Bergmann L., Mitrou PS, Helm EB, Scharrer I.[T-cell subpopulation in male homosexuals and patients with hemophilia and von Willebrand's syndrome]MMW Munch Med Wochenschr. 1983 Dec 2;125(48):1124-8. German. No abstract available.
198. Bergmann L., Helm EB, Nerger K, Schneider M, Tuengerthal S, Meier-Sydow J.[Pneumocystis carinii pneumonia in homosexual males with AIDS] Prax Klin Pneumol. 1983 Oct;37 Suppl 1:1035-8. German. No abstract available.
199. Staszewski S, Helm EB, Nerger KH, Bergmann L., Shah PM, Stille W.[Treatment of opportunistic infections in AIDS]MMW Munch Med Wochenschr. 1983 Sep 30;125(39):841-4. German. No abstract available.
200. Mitrou PS, Bergmann L., Tuengerthal S.[Induction of complete remission with adriamycin and cis-platinum in invasive thymoma] Dtsch Med Wochenschr. 1982 Nov 5;107(44):1667-70. German.
201. Mitrou PS, Fischer M, Bergmann L., Hübner K. [Sequential chemotherapy of malignant non-Hodgkin's lymphoma of high degree of malignancy in stages III and IV] Onkologie. 1982 Oct;5(5):222-7. German.
202. Bergmann L., Mitrou PS, Cherdron T, Holloway K, Jost J, Timm V, Zerth G.Expression of Ia-like antigen in lymphatic leukaemias and non-hodgkin lymphomas in correlation with other surface markers. Scand J Haematol. 1982 Sep;29(3):224-34.
203. Mitrou PS, Bergmann L., Holloway K, Zerth G.E-rosette formation in B-cell lymphatic leukemias induced by binding activity of monoclonal surface immunoglobulins to sheep red blood cells. Clin Immunol Immunopathol. 1981 Sep;20(3):346-53. No abstract available.
204. Bergmann L., Mitrou PS, Rogge H. Surface IgM kappa of prolymphocytic leukaemia cells with antibody activity to surface antigens of sheep and guinea-pig red blood cells. Br J Haematol. 1981 May;48(1):103-10.
205. Bergmann L., Walther F, Schubert JC, Martin H. The failure of splenectomy in Werlhof's disease.Verh Dtsch Ges Inn Med. 1975;81:1103-5.